Создание наноструктурных систем для транспорта лекарственных препаратов на основе смеси тритерпеноидов бересты (1091952), страница 27
Текст из файла (страница 27)
Mechanism of enhanced activity of liposome-entrappedaminoglycosides against resistant strains of Pseudomonas aeruginosa // Antimicrob. AgentsChemother. 2006. V. 50. P. 2016-2022.36. Halwani M., Mugabe C., Azghani A.O. Bactericidal efficacy of liposomal aminoglycosidesagainst Burkholderia cenocepacia // J. Antimicrob.
Chemother. 2007. V. 60. P. 760-769.37. Rukholm G., Mugabe C., Azghani A.O. Antibacterial activity of liposomal gentamicin againstPseudomonas aeruginosa: a time-kill study // Int. J. Antimicrob. Agents. 2006. V. 27. P. 247252.38. Halwani M., Blomme S., Suntres Z.E. Liposomal bismuth-ethanedithiol formulation enhancesantimicrobial activity of tobramycin // Int. J.
Pharm. 2008. V. 358. P. 278-284.39. Halwani M., Hebert S., Suntres Z.E. Bismuth-thiol incorporation enhances biological activitiesof liposomal tobramycin against bacterial biofilm and quorum sensing molecules production byPseudomonas aeruginosa // Int. J. Pharm. 2009. V. 373. P.
141-146.40. Alhariri M., Omri A. Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin afterintratracheal administration in rats with pulmonary pseudomonas aeruginosa infection //Antimicrob. Agents Chemother. 2013. V. 57. P. 569-578.41. Alhajlan M., Alhariri M., Omri A. Efficacy and safety of liposomal clarithromycin and its effecton pseudomonas aeruginosa virulence factors // Antimicrob. Agents Chemother.
2013. V. 57. P.2694-2704.42. Deng J.C., Moore T.A., Newstead M.W. CpG oligodeoxynucleotides stimulate protective innateimmunity against pulmonary Klebsiella infection // J. Immunol. 2004. V. 173. P. 5148-5155.14443. Puangpetch A., Anderson R., Huang Y.Y. Cationic liposomes extend the immunostimulatoryeffect of CpG oligodeoxynucleotide against Burkholderia pseudomallei infection in BALB/cmice // Clin.
Vaccine Immunol. 2012. V. 19. P. 675-683.44. Gaspar M.M., Cruz A., Penha A.F. Rifabutin encapsulated in liposomes exhibits increasedtherapeutic activity in a model of disseminated tuberculosis // Int. J. Antimicrob. Agents. 2008.V. 31. P. 37-45.45. Deol P., Khuller G.K., Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated inlung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice //Antimicrob.
Agents Chemother. 1997. V. 41. P. 1211-1214.46. Basu N., Sett R., Das P.K. Down-regulation of mannose receptors on macrophages afterinfection with Leishmania donovani // Biochem J. 1991. V. 277. P. 451-456.47. Rathore A., Jain A., Gulbake A. Mannosylated liposomes bearing Amphotericin B for effectivemanagement of visceral Leishmaniasis // J. Liposome Res. 2011. V. 21. P. 3333-3340.48. Cencig S., Coltel N., Truyens C. Parasitic loads in tissues of mice infected with Trypanosomacruzi and treated with AmBisome // PLoS Negl. Trop. Dis. 2011. V. 5 (6): е1216.49. Jadhav M.P., Shinde V.M., Chandrakala S. A randomized comparative trial evaluating the safetyand efficacy of liposomal amphotericin B (Fungisome) versus conventional amphotericin B inthe empirical treatment of febrile neutropenia in India // Indian J. Cancer.
2012. V. 49. P. 107113.50. Crystal R.G. Transfer of genes to humans: early lesions and obstacles to success // Science 270. 1995. Р. 404-410.51. Gao X., Huang L. Cationic liposome mediated gene transfer // Gene Ther. 1995. V. 2. P. 710722.52. Tomlinson E., Rolland A.P. Controllable gene therapy: pharmaceutics of non viral gene deliverysystems // J. Contr. Rel. 1996. V. 39.
P. 357-372.53. Sharma A., Sharma U.S. Liposomes in drug delivery: progress and limitations // Int. J. Pharm.1997. V. 154. P. 123-140.54. Zou Y., Zong G., Ling Y.H., Perez-Soler R. Development of cationic liposome formulations forintratracheal gene therapy of early lung cancer // Cancer Gene Ther. 2000. V. 7. P. 683-696.14555. Bandyopadhyay P., Kren B.T., Ma X., Steer C.J. Enhanced gene transfer into HuH-7 cells andprimary rat hepatocytes using targeted liposomes and polyethylenimine // Biotechniques. 1998.V. 25. P. 282-284.56. Kawaura C., Hasegawa S., Hirashima N., Nakanishi M.
Monosialoganglioside containingcationic liposomes with a cationic cholesterol derivative promote the efficiency of gene transfection in mammalian culture cells // Biol. Pharm. Bull. 2000. V. 23. P. 778-780.57. Ishiwata H., Suzuki N., Ando S., Kikuchi H., Kitagawa T. Characteristics and biodistribution ofcationic liposomes and their DNA complexes // J. Contr.
Rel. 2000. V. 69. P. 139-148.58. Ozpolat B., Sood A., Lopez-Berestein G. Nanomedicine based approaches for the delivery ofsiRNA in cancer // J. Intern. Med. 2010. V. 267. P. 44-53.59. Tseng Y.C., Mozumdar S., Huang L. Lipid-based systemic delivery of siRNA // Advanced DrugDelivery Reviews.
2009. V. 61. P. 721-731.60. Han S.E., Kang H., Shim G.Y. Novel cationic cholesterol derivative-based liposomes for serumenhanced delivery of siRNA // Int. J. Pharm. 2008. V. 353. P. 260-269.61. Spagnou S., Miller A.D., Keller M. Lipidic carriers of siRNA: differences in the formulation,cellular uptake, and delivery with plasmid DNA // Biochemistry. 2004. V.
43. P. 13348-13356.62. Sato A., Takagi M., Shimamoto A. Small interfering RNA delivery to the liver by intravenousadministration of galactosylated cationic liposomes in mice // Biomaterials. 2007. V. 28. P.1434-1442.63. Pirollo K.F., Chang E.H. Targeted delivery of small interfering RNA: approaching effectivecancer therapies // Cancer Res. 2008. V. 68. P. 1247-1250.64. Hughes J., Yadava P., Mesaros R. Liposomal siRNA delivery // Methods Mol. Biol. 2010. V.605.
P. 445-459.65. Gray M.J., Van Buren G., Dallas N.A. Therapeutic targeting of neuropilin-2 on colorectalcarcinoma cells implanted in the murine liver // J. Natl. Cancer Inst. 2008. V. 100. P. 109-120.66. Merritt W.M., Lin Y.G., Spannuth W.A. Effect of interleukin-8 gene silencing with liposomeencapsulated small interfering RNA on ovarian cancer cell growth // J. Natl. Cancer Inst. 2008.V. 100. P. 359-372.67. Ozpolat B., Akar U., Tekedereli I. Targeted silencing of Bcl-2 by liposomal siRNA- nanovectorsleads to autophagic and apoptotic cell death in in vivo breast cancer models // Proc. Annu.
Meet.Am. Assoc. Cancer Res. 2008: 4928.14668. Halder J., Kamat A.A., Landen C.N. Focal adhesion kinase targeting using in vivo shortinterfering RNA delivery in neutral liposomes for ovarian carcinoma therapy // Clin. Cancer Res.2006. V. 12. P. 4916-4924.69. Landen C.N., Chavez-Reyes A., Bucana C. Therapeutic EphA2 gene targeting in vivo usingneutral liposomal small interfering RNA delivery // Cancer Res. 2005. V. 65. P. 6910-6918.70.
Gewirtz A.M. On future's doorstep: RNA interference and the pharmacopeia of tomorrow // J.Clin. Invest. 2007. V. 117 (12). P. 3612-3614.71. Kapoor M., Burgess D.J. Efficient and safe delivery of siRNA using anionic lipids: formulationoptimization studies // Int. J. Pharm. 2012. V. 432. P. 80-90.72. Jeffs L.B., Palmer L.R., Ambegia E.G. A scalable, extrusion-free method for efficient liposomalencapsulation of plasmid DNA // Pharm. Res. 2005. V. 22. P. 362-372.73.
Gomes-da-Silva L.C., Fonseca N.A., Moura V. Lipid-based nanoparticles for siRNA delivery incancer therapy: paradigms and challenges // Acc. Chem. Res. 2012. V. 45. P. 1163-1171.74. Huang L., Liu Y. In vivo delivery of RNAi with lipid-based nanoparticles // Annu. Rev. Biomed.Eng.
2011. V. 13. P. 507-530.75. Morrissey D.V., Lockridge J.A., Shaw L. Potent and persistent in vivo anti-HBV activity ofchemically modified siRNAs // Nat. Biotechnol. 2005. V. 23. P. 1002-1007.76. Judge A.D., Robbins M., Tavakoli I. Confirming the RNAi-mediated mechanism of action ofsiRNA-based cancer therapeutics in mice // J. Clin. Invest. 2009. V.
119. P. 661-673.77. Akinc A., Querbes W., De S. Targeted delivery of RNAi therapeutics with endogenous andexogenous ligand-based mechanisms // Mol. Ther. 2010. V. 18. P. 1357-1364.78. Janes K.A., Calvo P., Alonso M.J. Polysaccharide colloidal particles as delivery systems formacromolecules // Adv. Drug Deliv. 2001. V. 47.
P. 83-97.79. Prabaharan M., Mano J.F. Chitosan-based particles as controlled drug delivery systems // DrugDeliv. 2005. V. 12. P. 41-57.80. Bodnar M., Hartmann J.F., Borbely J. Preparation and characterization of chitosan- basednanoparticles // Biomacromolecules. 2005. V. 6. P. 2521-2527.81. Calvo P., RemunanLopez C., VilaJato J.L., Alonso M.J.Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers // J.
Appl. Polym. Sci. 1997. V. 63. P. 125132.14782. Zhang H., Oh M., Allen C., Kumacheva E. Monodisperse chitosan nanoparticles for mucosaldrug delivery // Biomacromolecules. 2004. V. 5. P. 2461-2468.83. Xu Y.M., Du Y.M., Huang R.H., Gao L.P. Preparation and modification of N-(2-hydroxyl)propyl-3-trimethyl ammonium chitosan chloride nanoparticle as a protein carrier // Biomaterials.2003. V. 24. P. 5015-5022.84. Amidi M., Romeijn S.G., Borchard G., Junginger H.E., Hennink W.E., Jiskoot W.
Preparationand characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal deliverysystem // J. Control. Release . 2006. V. 111. P. 107-116.85. Sandri G., Bonferoni M.C., Rossi S., Ferrari F., Gibin S., Zambito Y., Di Colo G., CaramellaC. Nanoparticles based on N-trimethylchitosan: evaluation of absorption properties using in vitro(Caco-2 cells) and ex vivo (excised rat jejunum) models // Eur.
J. Pharm. Biopharm. 2007. V. 65.P. 68-77.86. Shi.X., Du.Y., Yang.J. Effect of degree of substitution and molecular weight of carboxymethylchitosan nanoparticles on doxorubicin delivery // J. Appl. Polym. Sci. 2006. V. 100. P. 46894696.87. You J.O., Peng C.A. Calcium-alginate nanoparticles formed by reverse micro- emulsion as genecarriers // Macromol. Symp. 2004. V. 219. P.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
